UPDATE: Credit Suisse Reiterates on Ariad Pharmaceuticals as Iclusig Re-Launch is Expected to be Bumpy

In a report published Monday, Credit Suisse analyst Jason Kantor reiterated a Neutral rating on Ariad Pharmaceuticals (NASDAQ: ARIA ), and raised the price target from $2.50 to $5.00. In the report, Credit Suisse noted, “Iclusig will be made available again in the US in January following the FDA's approval